News from ionis pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 12, 2022, 07:05 ET Ionis to present at RBC Capital Markets Global Healthcare Conference

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on...

May 04, 2022, 07:00 ET Ionis reports first quarter financial results and recent business achievements

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements. "We are...

May 02, 2022, 07:05 ET Ionis to host 2022 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a ...

Apr 20, 2022, 07:05 ET Ionis to hold first quarter 2022 financial results webcast

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4th at 11:30 a.m. Eastern Time to...

Apr 04, 2022, 00:15 ET Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its partner, AstraZeneca, today announced positive data from...

Mar 28, 2022, 07:30 ET Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078...

Mar 21, 2022, 07:05 ET Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences: Stifel 2022 Virtual...
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine

Mar 16, 2022, 19:16 ET Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the publication of positive Phase 2 data for...

Mar 07, 2022, 07:05 ET Ionis calls for applications for Janice Wiesman Young Investigator Grant Program

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program,...

Mar 01, 2022, 07:05 ET Ionis to present at the Cowen Annual Health Care Conference

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a panel discussion on orphan neurological disease...

Feb 24, 2022, 07:00 ET Ionis reports fourth quarter and full year 2021 financial results and recent business achievements

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent...

Feb 10, 2022, 07:05 ET Ionis to hold full year 2021 financial results webcast

CARLSBAD, Calif., Feb. 10, 2022 /PRNewswire/ – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on...

Jan 31, 2022, 07:05 ET Pfizer and Ionis announce discontinuation of vupanorsen clinical development program

Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development...

Jan 24, 2022, 07:05 ET Ionis announces eplontersen receives orphan drug designation from U.S. FDA

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA)...

Jan 19, 2022, 07:05 ET Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced two appointments that strengthen its leadership team and further position it to become a...

Jan 18, 2022, 00:05 ET Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in Huntington's ...

Jan 05, 2022, 07:05 ET Ionis to present at 40th Annual J.P. Morgan Healthcare conference

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at...

Jan 04, 2022, 07:30 ET Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a...

Dec 29, 2021, 02:00 ET Ionis and AstraZeneca close deal to develop and commercialize eplontersen

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the closing of the collaboration agreement with...

Dec 07, 2021, 02:00 ET Ionis and AstraZeneca to develop and commercialize eplontersen

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has entered into a strategic collaboration...

Dec 02, 2021, 15:03 ET Ionis to hold virtual investor day event

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a virtual investor day on Thursday, December 9th at 11:00 a.m. Eastern...

Nov 24, 2021, 06:30 ET Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly...

Nov 18, 2021, 13:30 ET Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE, the registrational study...

Nov 12, 2021, 07:05 ET Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the upcoming presentations of clinical and...

Nov 09, 2021, 07:05 ET Ionis to present at upcoming virtual investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following virtual...